Cargando…
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor. OBJECTIVES: To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin disease. METHODS: Two phase 3 t...
Autores principales: | Blauvelt, Andrew, Kircik, Leon, Papp, Kim A., Simpson, Eric L., Silverberg, Jonathan I., Kim, Brian S., Kwatra, Shawn G., Kuligowski, Michael E., Venturanza, May E., Wei, Shaoceng, Szepietowski, Jacek C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087253/ https://www.ncbi.nlm.nih.gov/pubmed/36066323 http://dx.doi.org/10.1111/jdv.18571 |
Ejemplares similares
-
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021) -
Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021) -
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
por: Bissonnette, Robert, et al.
Publicado: (2022) -
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022) -
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)